Examkin

Soru

Zorluk: ZorPharmacologic Interventions

An emergency physician evaluates a patient who was brought in by ambulance for severe, worsening shortness of breath.

The patient is a 52-year-old female who reports progressive chest tightness, wheezing, and a sensation of her heart racing that began early this morning. Her medical history is notable for severe persistent asthma, hypertension, and recently diagnosed hyperthyroidism for which she is awaiting endocrinology follow-up. She states that she ran out of her methimazole prescription two weeks ago. Current medications include high-dose inhaled fluticasone-salmeterol, an albuterol rescue inhaler, and oral amlodipine.

Vital signs are: Temperature 37.0°C (98.6°F), blood pressure 118/76 mmHg, pulse 148/min, respirations 26/min, and oxygen saturation 90% on room air.

Physical examination reveals a patient in visible respiratory distress using accessory muscles of respiration. Lung auscultation demonstrates diffuse, bilateral expiratory wheezing with a markedly prolonged expiratory phase.

A 12-lead electrocardiogram shows a narrow-complex, irregularly irregular tachycardia at a rate of 148/min with absent P waves. There are no ischemic ST-segment changes.

The patient is immediately placed on supplemental oxygen and started on continuous nebulized albuterol, ipratropium, and intravenous methylprednisolone. Thirty minutes later, her respiratory status improves slightly (oxygen saturation now 94%), but her heart rate remains elevated at 145/min, and she complains of ongoing uncomfortable palpitations.

Which of the following is the most appropriate pharmacologic intervention to manage her heart rate?

  1. Intravenous diltiazemCevap
  2. B
    Intravenous metoprolol tartrate
  3. C
    Intravenous adenosine
  4. D
    Intravenous digoxin
  5. E
    Intravenous amiodarone

Cevap

Intravenous diltiazem
The patient is presenting with an acute asthma exacerbation and concurrent atrial fibrillation with rapid ventricular response (AF RVR). In a hemodynamically stable patient, pharmacologic rate control is the primary goal. Non-dihydropyridine calcium channel blockers (e.g., diltiazem, verapamil) are the preferred agents for rate control in patients with severe reactive airway disease (asthma or COPD) because they effectively slow conduction through the AV node without inducing bronchospasm.

Adım Adım Çözüm

1
Interpret the clinical presentation and diagnostic data.
The patient is experiencing an acute severe asthma exacerbation and concurrent new-onset atrial fibrillation with rapid ventricular response (AF RVR).
The physical exam shows severe bronchospasm with accessory muscle use, and the ECG describes a narrow-complex, irregularly irregular rhythm lacking P waves.
2
Assess hemodynamic stability.
The patient is hemodynamically stable with a blood pressure of 118/76 mmHg.
Stability determines the need for immediate synchronized cardioversion versus pharmacologic rate control.
3
Select the most appropriate rate-control agent while accounting for absolute contraindications associated with her comorbidities.
Intravenous diltiazem is selected as the safest and most effective intervention.
Non-dihydropyridine calcium channel blockers effectively slow AV nodal conduction without exacerbating bronchoconstriction, avoiding the critical risks associated with beta-blockers in asthma or amiodarone in unmanaged hyperthyroidism.

Anahtar Kavram

Management of atrial fibrillation with rapid ventricular response (AF RVR) requires careful consideration of comorbidities. Non-dihydropyridine calcium channel blockers (diltiazem) are the preferred rate-control agents in patients with severe reactive airway disease.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru